

GOV. MSG. NO. 1245

EXECUTIVE CHAMBERS KE KE'ENA O KE KIA'ĀINA

JOSH GREEN, M.D. GOVERNOR KE KIA'ĀINA

June 29, 2023

The Honorable Ronald D. Kouchi President of the Senate, and Members of the Senate Thirty-Second State Legislature State Capitol, Room 409 Honolulu, Hawai'i 96813 The Honorable Scott K. Saiki Speaker, and Members of the House of Representatives Thirty-Second State Legislature State Capitol, Room 431 Honolulu, Hawai'i 96813

Dear President Kouchi, Speaker Saiki, and Members of the Legislature:

This is to inform you that on June 29, 2023, the following bill was signed into law:

HB1097 HD2 SD1

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT. ACT 162

Sincerely,

oh Green M.D.

Josh Green, M.D. Governor, State of Hawaiʻi

Approved by the Governor

on

JUN 2 9 2023

HOUSE OF REPRESENTATIVES THIRTY-SECOND LEGISLATURE, 2023 STATE OF HAWAII

2023-2323 HB1097 SD1 SMA.docx

A BILL FOR AN ACT

ACT 162

S.D. 1

1

H.B. NO. 1097 H.D. 2

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1	SECTION 1. Section 329-14, Hawaii Revised Statutes, is
2	amended as follows:
3	1. By amending subsection (d) to read:
4	"(d) [Any] Hallucinogenic substances. Unless specifically
5	excepted or unless listed in another schedule, any material,
6	compound, mixture, or preparation that contains any quantity of
7	the following hallucinogenic substances, including their salts,
8	isomers, and salts of isomers, [unless specifically excepted,]
9	whenever the existence of these salts, isomers, and salts of
10	isomers is possible within the specific chemical designation:
11	(1) Alpha-ethyltryptamine (AET);
12	(2) 2,5-dimethoxy-4-ethylamphetamine (DOET);
13	(3) 2,5-dimethoxyamphetamine (2,5-DMA);
14	(4) 3,4-methylenedioxy amphetamine;
15	(5) 3,4-methylenedioxymethamphetamine (MDMA);
16	(6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-
17	MDA);

H.B. NO. ¹⁰⁹⁷ H.D. 2 S.D. 1

1	(7)	3,4-methylenedioxy-N-ethylamphetamine (MDE);
2	(8)	5-methoxy-3,4-methylenedioxy-amphetamine;
3	(9)	4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);
4	(10)	4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
5	(11)	3,4,5-trimethoxy amphetamine;
6	(12)	Bufotenine;
7	(13)	4-methoxyamphetamine (PMA);
8	(14)	Diethyltryptamine;
9	(15)	Dimethyltryptamine;
10	(16)	<pre>4-methyl-2,5-dimethoxy-amphetamine;</pre>
11	(17)	Gamma hydroxybutyrate (GHB) (some other names include
12		gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-
13		hydroxybutanoic acid; sodium oxybate; sodium
14		oxybutyrate);
15	(18)	Ibogaine;
16	(19)	Lysergic acid diethylamide;
17	(20)	Marijuana;
18	(21)	Parahexyl;
19	(22)	Mescaline;
20	(23)	Peyote;
21	(24)	N-ethyl-3-piperidyl benzilate;

2023-2323 HB1097 SD1 SMA.docx

		1097
H.B.	N()	H.D. 2
		S.D. 1

1	(25)	N-methyl-3-piperidyl benzilate;
2	(26)	Psilocybin;
3	(27)	Psilocyn;
4	(28)	1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
5	(29)	Ethylamine analog of phencyclidine (PCE);
6	(30)	Pyrrolidine analog of phencyclidine (PCPy, PHP);
7	(31)	Thiophene analog of phencyclidine (TPCP; TCP);
8	(32)	Gamma-butyrolactone, including butyrolactone;
9		butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone
10		dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone;
11		1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-
12		hydroxybutyric acid lactone; 3-hydroxybutyric acid
13		lactone and 4-hydroxybutanoic acid lactone with
14		Chemical Abstract Service number 96-48-0 when any such
15		substance is intended for human ingestion;
16	(33)	1,4 butanediol, including butanediol; butane-1,4-diol;
17		1,4- butylenes glycol; butylene glycol; 1,4-
18		dihydroxybutane; 1,4- tetramethylene glycol;
19		tetramethylene glycol; tetramethylene 1,4- diol with
20		Chemical Abstract Service number 110-63-4 when any
21		such substance is intended for human ingestion;

2023-2323 HB1097 SD1 SMA.docx

1	(34)	2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7),
2		its optical isomers, salts, and salts of isomers;
3	(35)	N-benzylpiperazine (BZP; 1-benzylpiperazine) <u>,</u> its
4		optical isomers, salts, and salts of isomers;
5	(36)	1-(3-trifluoromethylphenyl)piperazine (TFMPP), its
6		optical isomers, salts, and salts of isomers;
7	(37)	Alpha-methyltryptamine (AMT) [, its isomers, salts, and
8		salts of isomers];
9	(38)	5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT)[, its
10		<pre>isomers, salts, and salts of isomers];</pre>
11	(39)	Salvia divinorum;
		Columnation D
12	(40)	Salvinorin A;
12 13	(40)	Divinorin A;
13	(41)	Divinorin A;
13 14	(41)	Divinorin A; 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some
13 14 15	(41)	<pre>Divinorin A; 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some trade or other names: 5-methoxy-3-[2- (dimethylamino)ethyl]indole; 5-MeO-DMT);</pre>
13 14 15 16	(41) (42)	<pre>Divinorin A; 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some trade or other names: 5-methoxy-3-[2- (dimethylamino)ethyl]indole; 5-MeO-DMT);</pre>
13 14 15 16 17	(41) (42) (43)	<pre>Divinorin A; 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some trade or other names: 5-methoxy-3-[2- (dimethylamino)ethyl]indole; 5-MeO-DMT); 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);</pre>
13 14 15 16 17 18	(41) (42) (43) (44)	<pre>Divinorin A; 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some trade or other names: 5-methoxy-3-[2- (dimethylamino)ethyl]indole; 5-MeO-DMT); 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E); 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);</pre>

2023-2323 HB1097 SD1 SMA.docx

1	(47)	2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-
2		2);
3	(48)	2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine
4		(2C-T-4);
5	(49)	2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
6	(50)	2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
7	(51)	2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
8	(52)	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-
9		methoxybenzyl)ethanamine, its optical, positional, and
10		geometric isomers, salts, and salts of isomers (Other
11		names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);
12	(53)	2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-
13		methoxybenzyl)ethanamine, its optical, positional, and
14		geometric isomers, salts, and salts of isomers (Other
15		names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); [and]
16	(54)	2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-
17		methoxybenzyl)ethanamine, its optical, positional, and
18		geometric isomers, salts, and salts of isomers (Other
19		names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) [-];
20	(55)	N-ethylhexedrone, its optical, positional, and
21		geometric isomers, salts, and salts of isomers (Other



1097 H.D. 2 S.D. 1 H.B. NO.

1		names: [alpha]-ethylaminohexanophenone; 2-
2		(ethylamino)-1-phenylhexan-1-one);
3	(56)	Alpha-pyrrolidinohexanophenone, its optical,
4		positional, and geometric isomers, salts, and salts of
5		isomers (Other names: [alpha]-PHP; [alpha]-
6		pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-
7		<pre>yl)hexan-1-one);</pre>
8	(57)	4-methyl-alpha-ethylaminopentiophenone, its optical,
9		positional, and geometric isomers, salts, and salts of
10		isomers (Other names: 4-MEAP; 2-(ethylamino)-1-(4-
11		<pre>methylphenyl)pentan-1-one);</pre>
12	(58)	4'-methyl-alpha-pyrrolidinohexiophenone, its optical,
13		positional, and geometric isomers, salts, and salts of
14		isomers (Other names: MPHP; 4'-methyl-alpha-
15		pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-
16		(pyrrolidin-1-yl)hexan-1-one);
17	(59)	Alpha-pyrrolidinoheptaphenone, its optical,
18		positional, and geometric isomers, salts, and salts of
19		isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-
20		<pre>yl)heptan-1-one);</pre>

2023-2323 HB1097 SD1 SMA.docx

1	(60)	4'-chloro-alpha-pyrrolidinovalerophenone, its optical,
2		positional, and geometric isomers, salts, and salts of
3		isomers (Other names: 4-chloro-[alpha]-PVP; 4'-
4		chloro-[alpha]-pyrrolidinopentiophenone; 1-(4-
5		chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one); and
6	(61)	2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one
7		(methoxetamine, MXE)."
8	2.	By amending subsection (g) to read:
9	" (g)	[Any] Cannabinoids. Unless specifically excepted or
10	unless li	sted in another schedule, any of the following
11	cannabino	ids, including their salts, isomers, and salts of
12	isomers,	[unless specifically excepted,] whenever the existence
13	of these	salts, isomers, and salts of isomers is possible within
14	the speci	fic chemical designation:
15	(1)	Tetrahydrocannabinols; meaning tetrahydrocannabinols
16		naturally contained in a plant of the genus Cannabis
17		(cannabis plant), as well as synthetic equivalents of
18		the substances contained in the plant, or in the
19		resinous extractives of Cannabis, sp. or synthetic
20		substances, derivatives, and their isomers with
21		similar chemical structure and pharmacological

2023-2323 HB1097 SD1 SMA.docx

Page 8

H.B. NO. ¹⁰⁹⁷ H.D. 2 S.D. 1

1		activity to those substances contained in the plant,
2		such as the following: Delta 1 cis or trans
3		tetrahydrocannabinol, and their optical isomers; Delta
4		6 cis or trans tetrahydrocannabinol, and their optical
5		isomers; and Delta 3,4 cis or trans-
6		tetrahydrocannabinol, and its optical isomers (since
7		nomenclature of these substances is not
8		internationally standardized, compounds of these
9		structures, regardless of numerical designation of
10		atomic positions, are covered);
11	(2)	Naphthoylindoles; meaning any compound containing a 3-
12		(1-naphthoyl)indole structure with substitution at the
13		nitrogen atom of the indole ring by a alkyl,
14		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
15		1-(N-methyl-2-piperidinyl)methyl or 2-(4-
16		morpholinyl)ethyl group, whether or not further
17		substituted in the indole ring to any extent and
18		whether or not substituted in the naphthyl ring to any
19		extent;
20	(3)	Naphthylmethylindoles; meaning any compound containing
21		a 1H-indol-3-yl-(1-naphthyl) methane structure with

2023-2323 HB1097 SD1 SMA.docx

H.B. NO. ¹⁰⁹⁷ H.D. 2 S.D. 1

substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;

Naphthoylpyrroles; meaning any compound containing a 8 (4) 9 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by a alkyl, 10 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 11 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl) 12 ethyl group whether or not further substituted in the 13 pyrrole ring to any extent, whether or not substituted 14 in the naphthyl ring to any extent; 15

16 (5) Naphthylmethylindenes; meaning any compound containing
17 a naphthylideneindene structure with substitution at
18 the 3-position of the indene ring by a alkyl,
19 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
20 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
21 ethyl group whether or not further substituted in the

2023-2323 HB1097 SD1 SMA.docx

Page 10

	Page 10	H.B. NO. ¹⁰⁹⁷ H.D. 2 S.D. 1
1		indene ring to any extent, whether or not substituted
2		in the naphthyl ring to any extent;
3	(6)	Phenylacetylindoles; meaning any compound containing a
4		3-phenylacetylindole structure with substitution at
5		the nitrogen atom of the indole ring by a alkyl,
6		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
7		1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
8		ethyl group whether or not further substituted in the
9		indole ring to any extent, whether or not substituted
10		in the phenyl ring to any extent;
11	(7)	Cyclohexylphenols; meaning any compound containing a
12		2-(3-hydroxycyclohexyl) phenol structure with
13		substitution at the 5-position of the phenolic ring by
14		a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
15		cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
16		2-(4-morpholinyl) ethyl group whether or not
17		substituted in the cyclohexyl ring to any extent;
18	(8)	Benzoylindoles; meaning any compound containing a 3-
19		(benzoyl) indole structure with substitution at the
20		nitrogen atom of the indole ring by a alkyl,
21		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,

2023-2323 HB1097 SD1 SMA.docx



1		1-(N-methyl-2-piperidinyl) methyl, or 2-(4-
2		morpholinyl) ethyl group whether or not further
3		substituted in the indole ring to any extent and
4		whether or not substituted in the phenyl ring to any
5		extent;
6	(9)	[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
7		pyrrolo[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-
8	• •	naphthalenylmethanone (another trade name is WIN
9		55,212-2);
10	(10)	(6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-
11		methyloctan-2-yl)-6a,7,10,10a-
12		tetrahydrobenzo[c]chromen-1-ol (Other trade names are:
13		HU-210/HU-211);
14	(11)	Tetramethylcyclopropanoylindoles; meaning any compound
15		containing a 3-tetramethylcyclopropanoylindole
16		structure with substitution at the nitrogen atom of
17		the indole ring by an alkyl, haloalkyl, cyanoalkyl,
18		alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
19		<pre>methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,</pre>
20		1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
21		morpholinyl)methyl, or tetrahydropyranylmethyl group,

2023-2323 HB1097 SD1 SMA.docx

H.B. NO. ¹⁰⁹⁷ H.D. 2 S.D. 1

1		whether or not further substituted in the indole ring
2		to any extent and whether or not substituted in the
3		tetramethylcyclopropyl ring to any extent;
4	(12)	N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,
5		its optical, positional, and geometric isomers, salts,
6		and salts of isomers (Other names: APINACA, AKB48);
7	(13)	Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its
8		optical, positional, and geometric isomers, salts, and
9		salts of isomers (Other names: PB-22; QUPIC);
10	(14)	Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-
11		carboxylate, its optical, positional, and geometric
12		isomers, salts, and salts of isomers (Other names: 5-
13		fluoro-PB-22; 5F-PB-22);
14	(15)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
15		fluorobenzyl)-1H-indazole-3-carboxamide, its optical,
16		positional, and geometric isomers, salts, and salts of
17		isomers (Other names: AB-FUBINACA);
18	(16)	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
19		indazole-3-carboxamide, its optical, positional, and
20		geometric isomers, salts, and salts of isomers (Other
21		names: ADB-PINACA);

2023-2323 HB1097 SD1 SMA.docx

			1097
Η	.В.	NO.	H.D. 2 S.D. 1
			3.D. I

1	(17)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
2		(cyclohexylmethyl)-1H-indazole-3-carboxamide, its
3		optical, positional, and geometric isomers, salts, and
4		salts of isomers (Other names: AB-CHMINACA);
5	(18)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
6		indazole-3-carboxamide, and geometric isomers, salts,
7		and salts of isomers (Other names: AB-PINACA);
8	(19)	[1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-
9		yl)methanone, and geometric isomers, salts, and salts
10		of isomers (Other names: THJ-2201);
11	(20)	Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-
12		valinate, and geometric isomers, salts, and salts of
13		isomers (Other names: FUB-AMB, Methyl 2-(1-(4-
14		fluorobenzyl)-1H-indazole-3-carboxamido)-3-
15		<pre>methylbutanoate, MMB-FUBINACA, AMB-FUBINACA);</pre>
16	(21)	(S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
17		carboxamido)-3-methylbutanoate, and geometric isomers,
18		salts, and salts of isomers (Other names: 5-fluoro-
19		AMB, 5-fluoro-AMP);
20	(22)	N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-
21		indazole-3-carboxamide, and geometric isomers, salts,

2023-2323 HB1097 SD1 SMA.docx

•	*	
1		and salts of isomers (Other names: AKB48 N-(5-
2		fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl
3		analog, 5F-APINACA);
4	(23)	N-adamantyl-1-fluoropentylindole-3-Carboxamide, and
5		geometric isomers, salts, and salts of isomers (Other
6		names: STS-135, 5F-APICA; 5-fluoro-APICA);
7	(24)	Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
8		carboxylate, and geometric isomers, salts, and salts
9		of isomers (Other names: NM2201; CBL2201);
10	(25)	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
11		(cyclohexylmethyl)-1H-indazole-3-carboxamide, and
12		geometric isomers, salts, and salts of isomers (Other
13		names: MAB-CHMINACA and ADB-CHMINACA);
14	(26)	Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-
15		carboxamido]-3,3-dimethylbutanoate (Other names: 5F-
16		ADB, [5-flouro-ADB,] <u>5-fluoro-ADB,</u> and 5F-MDMB-
17		PINACA), its optical, positional, and geometric
18	-	isomers, salts, and salts of isomers;
19	(27)	1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-lH-indazole-
20		3-carboxamide, its optical, positional, and geometric
21		isomers, salts, and salts of isomers (Other names:



Page 15

1		SGT-78; 4-CN-CUMYL BINACA; 4-CN-CUMYL-BUTINACA; CUMYL-
2		CB-PINACA; CUMYL-CYBINACA; 4-cyano-CUMYL-BUTINACA;
3		CUMYL-4CN-BINACA);
4	(28)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-
5		fluoropentyl)-1H-indazole-3-carboxamide (Other name:
6		5F-AB-PINACA);
7	(29)	Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-
8		carboxamido)-3-methylbutanoate (Other names: MMB-
9		CHMICA; AMB-CHMICA);
10	(30)	1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-
11		pyrrolo[2,3-b]pyridine-3-carboxamide (Other names: 5F-
12		CUMYL-P7AICA); [and]
13	(31)	Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-
14		3-carboxamido)butanoate (MDMB-4en-PINACA) [-];
15	(32)	Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
16		carboxamido)-3,3-dimethylbutanoate (Other name: 5F-
17		EDMB-PINACA);
18	(33)	Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-
19		3,3-dimethylbutanoate (Other names: 5F-MDMB-PICA; 5F-
20	· .	MDMB-2201);

1	(34)	N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-	
2		carboxamide (Other names: FUB-AKB48; FUB-APINACA;	
3		AKB48 N-(4-FLUOROBENZYL));	
4	(35)	<u>1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-</u>	
5		indazole-3-carboxamide (Other names: 5F-CUMYL-PINACA;	
6		SGT-25); and	
7	(36)	(1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-	
8		tetramethylcyclopropyl)methanone (Other name: FUB-	
9		<u>144).</u> "	
10	SECTION 2. Section 329-20, Hawaii Revised Statutes, is		
11	amended by amending subsection (b) to read as follows:		
12	" (b)	Depressants. [Any] <u>Unless specifically excepted or</u>	
13	<u>unless li</u>	sted in another schedule, any material, compound,	
14	mixture,	or preparation [which] <u>that</u> contains any quantity of	
15	the follo	wing substances, including its salts, isomers, esters,	
16	ethers, and salts of isomers, whenever the existence of these		
17	isomers,	esters, ethers, and salts is possible within the	
18	specific	chemical designation, that has a degree of danger or	
19	probable	danger associated with a depressant effect on the	
20	central n	ervous system:	
21	(1)	Alprazolam;	

2023-2323 HB1097 SD1 SMA.docx

1	(2)	Barbital;		
2	(3)	Brexanolone;		
3	(4)	Bromazepam;		
4	(5)	Butorp	hanol;	
5	(6)	Camaze	pam;	
6	(7)	Cariso	prodol;	
7	(8)	Chlora	l betaine;	
8	(9)	Chlora	l hydrate;	
9	(10)	Chlordiazepoxide;		
10	(11)	Clobazam;		
11	(12)	Clonaz	epam;	
12	(13)	Clorazepate;		
13	(14)	Clotiazepam;		
14	(15)	Cloxaz	olam;	
15	(16)	Darido	rexant;	
16	[(16)]	(17)	Delorazepam;	
17	[(17)]	(18)	Diazepam;	
18	[(18)]	(19)	Dichloralphenazone	(Midrin);
19	[-(19)]	(20)	Estazolam;	
20	[(20)]	(21)	Ethchlorvynol;	
21	[(21)]	(22)	Ethinamate;	·

2023-2323 HB1097 SD1 SMA.docx

- 1 [(22)] (23) Ethyl loflazepate;
- 2 [(23)] (24) Fludiazepam;
- 3 [<u>(24)</u>] (25) Flunitrazepam;
- 4 [(25)] (26) Flurazepam;
- 5 [(26)] (27) Fospropofol (Lusedra);
- 6 [(27)] (28) Halazepam;
- 7 [(28)] (29) Haloxazolam;
- 8 [<u>(29)</u>] (30) Ketazolam;
- 9 [(30)] (31) Lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-
- 10 5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-
- 11 2-y1)cyclopropane-1-carboxamide);
- 12 [-(31)] (32) Loprazolam;
- 13 [(32)] (33) Lorazepam;
- 14 [(33)] (34) Lormetazepam;
- 15 [(34)] (35) Mebutamate;
- 16 [(35)] (36) Medazepam;
- 17 [(36)] (37) Meprobamate;
- 18 [(37)] (38) Methohexital;
- **19** [(38)] (39) Methylphenobarbital (mephorbarbital);
- 20 [(39)] (40) Midazolam;
- 21 [(40)] (41) Nimetazepam;



1097 H.D. 2 S.D. 1 H.B. NO.

1	[(41)] <u>(42)</u>	Nitrazepam;
2	[(42)] <u>(43)</u>	Nordiazepam;
3	[(43)] <u>(44)</u>	Oxazepam;
4.	[(44)] <u>(45)</u>	Oxazolam;
5	[(45)] <u>(46)</u>	Paraldehyde;
6	[(46)] <u>(47)</u>	Petrichloral;
7	[(47)] <u>(48)</u>	Phenobarbital;
8	[(48)] <u>(49)</u>	Pinazepam;
9	[(49)] <u>(50)</u>	Prazepam;
10	[(50)] <u>(51)</u>	Quazepam;
11	[(51)] <u>(52)</u>	Remimazolam;
12	[(52)] <u>(53)</u>	Suvorexant;
13	[(53)] <u>(54)</u>	Temazepam;
14	[(54)] <u>(55)</u>	Tetrazepam;
15	[(55)] <u>(56)</u>	Triazolam;
16	[(56)] <u>(57)</u>	Zaleplon;
17	[(57)] <u>(58)</u>	Zolpidem; and
18	[(58)] <u>(59)</u>	Zopiclone (Lunesta)."
19	SECTION 3.	Section 329-22, Hawaii Revised Statutes, is
20	amended by amen	ding subsection (d) to read as follows:

2023-2323 HB1097 SD1 SMA.docx

19

"(d) Depressants. Unless specifically exempted or 1 excluded or unless listed in another schedule, any material, 2 compound, mixture, or preparation that contains any quantity of 3 the following substances having a depressant effect on the 4 central nervous system, including its salts, isomers, and salts 5 6 of isomers: Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-7 (1) yl]butanamide) (Other names: BRV; UCB-34714; 8 Briviact) and its salts; 9 Ganaxolone (3[alpha]-hydroxy-3[beta]-methyl-5[alpha]-10 (2) 11 pregnan-20-one); [(2)] (3) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-12 propionamide], (Vimpat); 13 [(3)] (4) Lasmiditan (2,4,6-trifluoro-N-(6-(1-14 methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide); 15 16 and [(4)] (5) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic 17 acid]." 18 SECTION 4. Statutory material to be repealed is bracketed 19 and stricken. New statutory material is underscored. 20

2023-2323 HB1097 SD1 SMA.docx

20

1097 H.D. 2

H.B. NO.

1

H.B. NO. H.D. 2

SECTION 5. This Act shall take effect upon its approval.

APPROVED this 29th day of June, 2023

GOVERNOR OF THE STATE OF HAWAII



HB No. 1097, HD 2, SD 1

THE HOUSE OF REPRESENTATIVES OF THE STATE OF HAWAII

Date: April 27, 2023 Honolulu, Hawaii

We hereby certify that the above-referenced Bill on this day passed Final Reading in the House of Representatives of the Thirty-Second Legislature of the State of Hawaii, Regular Session of 2023.

(60

Scott K. Saiki Speaker House of Representatives

Hili , lite

Brian L. Takeshita Chief Clerk House of Representatives

THE SENATE OF THE STATE OF HAWAI'I

Date: March 30, 2023 Honolulu, Hawai'i 96813

We hereby certify that the foregoing Bill this day passed Third Reading in the Senate

of the Thirty-Second Legislature of the State of Hawai'i, Regular Session of 2023.

President of the Senate

Clerk of the Senate